GAA
FBLG icon

Global Assets Advisory’s FibroBiologics FBLG Stock Holding History

Global Assets Advisory’s Portfolio FBLG Stock Details FBLG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-523
Closed -$2.35K – 567
2025
Q4 		$2.35K Sell
523
-12
-2% -$85 ﹤0.01% 282
2025
Q3 		$5.84K Buy
+535
New +$6.41K ﹤0.01% 279

Other funds holding FBLG

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FEG
Fund Evaluation Group Cincinnati, Ohio $3.25B AUM 14.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CFP
Cascade Financial Partners San Diego, California $970M AUM 19.9% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
VGA
Vanguard Global Advisers Malvern, Pennsylvania $187B AUM

Global Assets Advisory's FBLG Position: Q1 2026 in Review

Global Assets Advisory sold out of FibroBiologics (FBLG) in Q1 2026, closing a stake of 523 shares — an estimated $2.35K sold.

Global Assets Advisory first reported a position in FBLG in Q3 2025 and held it in 2 quarters. The position peaked at $5.84K in Q3 2025. 17 funds tracked by Wall St. Rank hold FBLG as of Q1 2026.

  • Global Assets Advisory reported no remaining FibroBiologics position as of Q1 2026 after selling out during the quarter.
  • Global Assets Advisory sold 523 FibroBiologics shares in Q1 2026, an estimated $2.35K.
  • Global Assets Advisory first reported a position in FibroBiologics in Q3 2025 and held it in 2 quarters.
  • Global Assets Advisory's FibroBiologics position peaked at $5.84K in Q3 2025.
  • 17 funds tracked by Wall St. Rank held FibroBiologics as of Q1 2026.

Based on Global Assets Advisory's 13F filing for Q1 2026, filed 1 May 2026.